TECH
Bio-Techne CorporationEvidence as of 2026-09-03Overview · Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagn…
Management team
- Mr. David Clair C.F.A. · VP of Investor Relations & Corporate DevelopmentFind on LinkedIn
- Ms. Cheryl Bethune · Senior VP & Chief Human Resources OfficerFind on LinkedIn
- Mr. Martin Wirtz · Senior Vice President of Strategy & Corporate DevelopmentFind on LinkedIn
- Dr. Matthew F. McManus M.D., MBA, Ph.D. · President of Diagnostics & GenomicsFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.3 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The evidence balance is Mixed (+0.3 of a possible +2; confidence high). Filings-based operating results across the three fiscal quarters in 2026 show sequential increases: revenues rose from $ 286,555,000 in Q1 2026 (fiscal quarter ended 2025-10-30) to $ 295,877,000 in Q2 2026 (fiscal quarter ended 2026-01-29) and to $ 311,415,000 in Q3 2026 (fiscal quarter ended 2026-04-29). Gross profit moved from $ 188,112,000 to $ 191,277,000 to $ 208,288,000 over the same quarters, and operating income climbed from $ 47,658,000 to $ 54,461,000 to $ 75,495,000.
Valuation- and cash-flow evidence shows trailing twelve‑month FCF of $ 169,255,000 (FCF per share $ 1.0753 with 156,818,238 shares outstanding as of 2026-08-17), trailing multiples of price/FCF = 67.24, EV/EBITDA = 34.18 and P/E (ttm) = 76.91, and an implied FCF growth assumption of 41.61% embedded by today’s price under the stated model. The filings also record cash of $ 264,712,000 as of 2026-06-30 and an enterprise value of $ 11,073,246,607; together these items make capital structure and EV material to the valuation picture, although detailed debt data are absent.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenues for the three fiscal quarters in 2026 reported in the 10-Q filing moved from $286,555,000 in fiscal Q1 2026 (2025-07-01 to 2025-09-30) to $295,877,000 in fiscal Q2 2026 (2025-10-01 to 2025-12-31) and to $311,415,000 in fiscal Q3 2026 (2026-01-01 to 2026-03-31).
XBRL companyfacts · 0001104659-26-056302Gross profit in those same fiscal quarters reported in the 10-Q filing was $188,112,000 in fiscal Q1 2026, $191,277,000 in fiscal Q2 2026, and $208,288,000 in fiscal Q3 2026 (three-month periods stated above).
XBRL companyfacts · 0001104659-26-056302Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Nothing in this slice of the evidence rose to a claim — a quiet read, which itself is information.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
No computed signal history for this symbol yet — signals need roughly 70 trading days of price history.
Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02T13:45:47.228469+00:00 the security is a holding in the iShares Core S&P 500 ETF (IVV) with a weight of 0.02% of that fund.
ETF constituents · market dataThe provided evidence shows a single ETF membership record and does not show membership weights in other ETFs or passive funds.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
A finance.yahoo.com headline published 2 September 2026 framed a single tech-stock story as a value opportunity with 'roughly 130% upside' and referenced Zacks estimates and other fundamentals.
News · finance.yahoo.com · 2026-09-02An ibtimes.com headline published 2 September 2026 focused on Palantir's CEO becoming the lead investor in a startup associated with Ukraine's ousted defense minister and noted the investment size was not disclosed.
News · ibtimes.com · 2026-09-02Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model reports an implied free cash flow (FCF) growth rate of 41.61% (0.4161) that today’s price would justify under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve‑month valuation multiples in the evidence are: price/FCF = 67.24, EV/EBITDA = 34.18, and P/E (ttm) = 76.91.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
The company’s reported quarterly operating performance in 2026 shows sequential revenue, gross profit, and operating income expansion across Q1–Q3, and a notable lift in quarterly net income and diluted EPS in Q3; these operating-line improvements support a constructive reading of recent fundamentals. Trailing twelve‑month FCF and operating metrics (FCF $169.3M; operating income ttm $216.3M; DDA ttm $107.7M) and a cash balance of $264.7M indicate material cash generation and balance-sheet liquidity underpinning the firm’s enterprise value. Combined, the filings-based momentum and meaningful trailing cash generation help justify why the market might be pricing in elevated future cash-flow expectations (the model’s implied FCF growth and multiples show the market is valuing significant optionality). Finally, the presence in a major S&P 500 ETF (albeit a small weight) and at least one outlet framing a value opportunity are supportive of investor interest and multiple channels of attention.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.39
18 surviving claims rest on 8 distinct sources; the heaviest analyst carries 33% of them, and 94% of what the desk raised survived the debate.
Eighteen surviving claims drawn from eight sources gives moderate breadth, but the fact that one analyst contributed a third of the surviving claims and that 94% of proposed points survived debate indicates the read is relatively consolidated around a consistent interpretation. In fragility terms, the evidence is informative but somewhat dependent on a few key voices and core documents — treat headline conclusions as provisionally supported rather than broadly corroborated across many independent sources.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
13 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.6 to the score
1 holdings record
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
3 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on TECH Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.